doi:10.1001/jamanetworkopen.2024.57349
What are the risks of skin whitening injection
When to contact your GP, diabetes team, or healthcare professional: Severe or persistent nausea and vomiting preventing adequate fluid or food intake Signs of dehydration (dark urine, dizziness, reduced urination) Severe abdominal pain, particularly if accompanied by vomiting, or right upper abdominal pain with fever Symptoms of hypoglycaemia that don't resolve with usual treatment Unexplained weight loss exceeding clinical targets Changes in mood or suicidal thoughts Any concerns about medication tolerance or effectiveness The MHRA continues to monitor the safety profile of incretin medications through the Yellow Card scheme
Additionally, the deficiency and inhibition of HDAC3 reduces the profibrotic gene expression and decreases the number and activation of myofibroblasts, ultimately alleviating UUO-induced renal fibrosis (Wang et al., 2024b)
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, such as type 2 diabetes or hypertension
